Maui Derm Virtual Congress

Wednesday, June 24, 2020, 8:00 AM - Saturday, June 27, 2020, 5:00 PM, Virtual Live Internet

AMA PRA Category 1 Credits™ (29.25 hours), AMA PRA Category 1 Credits™ Designated (29.25 hours)

Due to the COVID-19 pandemic and concern for the health and safety our meeting attendees, faculty, and industry representatives, coupled with the uncertainty of travel restrictions, this meeting is being conducted in lieu of our live meetings through summer 2020.

A four-day, COVID-19-safe, dermatology CME conference for only $99, including:

• Live-stream lectures from June 24-27 with presenters on-screen providing real-time commentary and Q&A with attendees. (CME)
• Designed for the entire community of dermatology health care professionals, including dermatologists and dermatology NPs and PAs.
• A bonus Q&A Webinar series on Sunday, June 28 to address your most pressing questions from the Virtual Congress. (non-CME)
• Plus, On-Demand Access to all lectures and workshops, at any time, for up to 2 months. (non-CME)
• Broadcast with state-of-the-art technology assuring video and audio quality.
• Earn up to 29.25 AMA PRA Category 1 Credits™ during live-stream event.
• Lectures and workshops from our world-class faculty.
• Virtual exhibit halls and product theaters featuring top companies in the industry.
• A safe alternative to a live, in-person CME conference.

To register, please go to: https://mauiderm.com/maui-derm-virtual-congress-registration-2-2-2/

Maui Derm Virtual Congress Registration

Live-Stream Virtual Meeting • June 24-27, 2020

Begins on June 24th at 8:00 AM Mountain Time and Ends on June 27th at 5:00 MT

Q&A Webinar • June 28, 2020 - No CMEs 

Registration is $99 and includes all four days of the live-stream meeting and access to Maui Derm Virtual Congress On-Demand for up to 2 months.

1. Review the pathogenesis of various dermatological conditions such as infectious diseases, psoriasis, psoriatic arthritis, acne vulgaris, rosacea, hidradenitis, contact dermatitis, atopic dermatitis, eczema, pruritus, actinic keratoses, melanoma and non-melanoma skin cancer, pediatric skin disorders, connective tissue disorders, granulomatous disorders of the skin, connective tissue
2. Cite the mechanisms of action of various drugs, including topical and systemic therapies, as well as immunomodulatory agents that are commonly prescribed by the nurse practitioner and physician assistant practicing in dermatology and identify patients in your practice for whom these therapies may be appropriate
3. Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving surgical and cosmetic procedures in order to set realistic expectations and maximize therapeutic outcomes
4. Describe potential adverse events, safety, tolerance and resistance issues that may be related to the use of various drugs and therapies prescribed by clinicians in dermatology as well as therapeutic modalities including: topical and systemic corticosteroids, newer biologic agents, including TNF antagonists, T-cell and B-cell targeted therapies, anti-IL-12/23 therapies, IL-23 & IL-17 antibodies, systemic and topical PDE4 inhibitors, JAK inhibitors, anti-IgE and anti-IL 4 receptor, systemic retinoids, methotrexate, cyclosporine, neurokinin-1 receptor antagonists, systemic and topical acne/rosacea therapies, systemic hidradenitis suppuritiva therapies, oral and topical antibiotics, antifungals, anti-viral therapies, wound healing agents, antihistamines, calcineurin inhibitors, topical skin lightening agents, sunscreens, topical and systemic retinoids, 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, hedgehog pathway inhibitors, rituximab, BRAF/MEK inhibitors, CTLA-4 and PD-1/PDL-1 inhibitors, botulinum toxins, dermal filler agents including hyaluronic acid, collagen, polylactic acid, hydroxyappetite based fillers, and implement appropriate management strategies in order to reduce these adverse effects and optimize patient outcomes
5. Assess the data around emerging and novel therapeutics for a variety of dermatologic diseases and develop treatment algorithms and management strategies for the optimal use of these therapies
6. Discuss the importance of clinician/patient communication regarding benefit versus risk, patient satisfaction, and adherence when selecting therapies for patients

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Advances in Cosmetic and Medical Dermatology.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live internet activity for a maximum of 29.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

No faculty are available for this activity at this time.